Pancreatic Beta Cell Therapy
Type 1 Diabetes
PreclinicalActive
Key Facts
About Syntax Bio
Syntax Bio is a private, preclinical-stage biotech leveraging AI and synthetic biology to program stem cell differentiation. Its core Cellgorithm platform uses epigenetic instructions to rapidly and reliably generate therapeutic cell types, potentially cutting development timelines from months to days. The company operates a capital-efficient partnership model with biopharma, is backed by notable venture investors, and has an initial program in pancreatic beta cells for Type 1 Diabetes supported by Breakthrough T1D. Syntax aims to be a force multiplier for the cell therapy industry by addressing scalability, cost, and reliability challenges.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |